Natural Killer NK Cell Lymphoma Pipeline Expands with 100+ Companies Leading Innovation - DelveInsight | NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Innate Pharma, Affimed Therapeutics AG, Wugen

With groundbreaking advancements from industry leaders, the Natural Killer NK Cell Lymphoma pipeline continues to grow, redefining treatment strategies and improving patient outcomes.

DelveInsight's "Natural Killer NK Cell Lymphoma Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Natural Killer NK Cell Lymphoma market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging Natural Killer NK Cell Lymphoma drugs, the Natural Killer NK Cell Lymphoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Natural Killer NK Cell Lymphoma Pipeline Report
• DelveInsight's Natural Killer NK Cell Lymphoma Pipeline analysis depicts a robust space with 100+ active players working to develop 140+ pipeline drugs for Natural Killer NK Cell Lymphoma treatment.
• The leading Natural Killer NK Cell Lymphoma companies include ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Innate Pharma, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Kuur Therapeutics (Formerly Cell Medica), and others are evaluating their lead assets to improve the Natural Killer NK Cell Lymphoma treatment landscape.
• Key Natural Killer NK Cell Lymphoma pipeline therapies in various stages of development include ALT 803, Bemarituzumab, Monalizumab, NKTR-214 (Bempegaldesleukin), Nidanilimab, Pidilizumab, SD-101, BVAC-C, PD-L1.t-haNK, K-NK002, Enkastim, ALECSAT, CellProtect, Nk-92, haNk, MG4101, Imprime PGG, Lirilumab, IPH4102, AFM-13, WU-NK-101, ABX196, AFM24, PNK-007, Allogeneic Natural Killer Cell Therapy (oNKord), FLYSYN, KNK-ID-101, GTB-3550, CAR-NK cells, DF1001, DF-6002, NKG2D-ACE2 CAR-NK Cells, AB-101, SNK01, NKTR-225, and others.
• In August 2024, Indapta Therapeutics received FDA IND clearance for its Phase 1 trial of IDP-023, a g-NK cell therapy for progressive multiple sclerosis.
• In June 2024, GT Biopharma secured FDA IND clearance to initiate a Phase 1 trial of GTB-3650 for CD33+ leukemia.
• In May 2024, the FDA granted orphan drug designation to IGNK001 (Gengleucel) for the treatment of acute myeloid leukemia (AML).
• In April 2024, the FDA also granted orphan drug designation to IGNK001 (Gengleucel) for AML.

Request a sample and discover the recent breakthroughs happening in the Natural Killer NK Cell Lymphoma pipeline landscape @ https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Natural Killer NK Cell Lymphoma Overview
Natural killer cells, also known as NK cells, are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and virus-infected cells. NK cell abnormalities have been observed in several cancer patients, including decreased cytotoxicity, defective expression of activating receptors or intracellular signaling molecules, overexpression of inhibitory receptors, defective proliferation, and decreased numbers in peripheral blood and tumor infiltrate, and defective cytokine production.
NK cell therapy has been most successful in hematopoietic malignancies, such as leukemias. NK cell immunotherapy can be achieved by either activating endogenous NK cell response by administering NK stimulants or using exogenous NK cells via HSCT or adoptive cell transfer. Several strategies for NK cell immunotherapies for human cancer have been proposed to date. NK cell immunotherapy can be achieved in several ways.

Find out more about Natural Killer NK Cell Lymphoma medication @ https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Natural Killer NK Cell Lymphoma Treatment Analysis: Drug Profile
Monalizumab: Innate Pharma
Monalizumab (IPH2201) is a first-in-class humanized IgG4 antibody that targets NKG2A receptors on tumor-infiltrating cytotoxic NK and CD8 T cells. Developed by Innate Pharma, it is currently in Phase III trials for Squamous Cell Carcinoma of the Head and Neck and Phase II for gynecological cancers, chronic lymphocytic leukemia, and head and neck cancer. Additionally, it is in Phase I trials for advanced solid tumors and hematologic malignancies.

NKTR-214 (Bempegaldesleukin): Nektar Therapeutics
NKTR-214 is designed to enhance the body's cancer-fighting immune response by expanding tumor-infiltrating lymphocytes (TILs), including cancer-killing T cells and NK cells. It works by targeting CD122-specific receptors on CD8+ effector T cells and NK cells, which are crucial for immune cell proliferation. CD122, also known as the Interleukin-2 receptor beta subunit, plays a key role in boosting these immune responses.

Key Natural Killer NK Cell Lymphoma Therapies and Companies
• Monalizumab: Innate Pharma
• NKTR-214 (Bempegaldesleukin): Nektar Therapeutics
• ALT 803: ImmunityBio
• ALECSAT: CytoVac
• PNK-007: Celularity

Learn more about the novel and emerging Natural Killer NK Cell Lymphoma pipeline therapies @ https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Natural Killer NK Cell Lymphoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intracranial
• Intramuscular
• Intratumoral
• Intravenous
• Intravenous
• Parenteral
• Subcutaneous

By Molecule Type
• Small molecule
• Antibodies
• Beta Glucans
• CAR-NK cell therapy
• Cell Therapy
• Gene therapies
• Glycolipid
• NK Cell therapy
• NK T-Cell therapy
• Oligodeoxyribonucleotides
• Proteins
• RNA
• Stem cell therapies
• Vaccines

Scope of the Natural Killer NK Cell Lymphoma Pipeline Report
• Coverage: Global
• Key Natural Killer NK Cell Lymphoma Companies:ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Innate Pharma, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Kuur Therapeutics (Formerly Cell Medica), and others.
• Key Natural Killer NK Cell Lymphoma Pipeline Therapies: ALT 803, Bemarituzumab, Monalizumab, NKTR-214 (Bempegaldesleukin), Nidanilimab, Pidilizumab, SD-101, BVAC-C, PD-L1.t-haNK, K-NK002, Enkastim, ALECSAT, CellProtect, Nk-92, haNk, MG4101, Imprime PGG, Lirilumab, IPH4102, AFM-13, WU-NK-101, ABX196, AFM24, PNK-007, Allogeneic Natural Killer Cell Therapy (oNKord), FLYSYN, KNK-ID-101, GTB-3550, CAR-NK cells, DF1001, DF-6002, NKG2D-ACE2 CAR-NK Cells, AB-101, SNK01, NKTR-225, and others.

Dive deep into rich insights for drugs used for Natural Killer NK Cell Lymphoma treatment; visit @ https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Natural Killer NK Cell Lymphoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Natural Killer NK Cell Lymphoma Pipeline Therapeutics
6. Natural Killer NK Cell Lymphoma Pipeline: Late-Stage Products (Phase III)
7. Natural Killer NK Cell Lymphoma Pipeline: Late-Stage Products (Phase III)
8. Natural Killer NK Cell Lymphoma Pipeline: Mid-Stage Products (Phase II)
9. Natural Killer NK Cell Lymphoma Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.